Properties (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:chemicalFormula |
C20H22N4O4S
|
| gptkbp:clinicalTrials |
gptkb:United_States
gptkb:Omid_Therapeutics Europe Phase 1 Phase 2 Phase 3 |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:community_service |
genetic mutations
specific protein expression |
| gptkbp:contraindication |
cardiovascular issues
liver toxicity kidney toxicity |
| gptkbp:developedBy |
gptkb:Omid_Therapeutics
|
| gptkbp:dosageForm |
tablet
solution |
| gptkbp:drugInterdiction |
other chemotherapy agents
|
| gptkbp:formulation |
oral
injectable |
| gptkbp:future_plans |
clinical trials
|
| gptkbp:healthcare |
age 18 and older
diagnosed with cancer |
| https://www.w3.org/2000/01/rdf-schema#label |
Omid-17
|
| gptkbp:impact |
varies by protocol
|
| gptkbp:marketSegment |
not yet marketed
|
| gptkbp:origin |
synthetic
|
| gptkbp:patentStatus |
patented
|
| gptkbp:regulatoryCompliance |
investigational new drug
|
| gptkbp:releaseYear |
2020
|
| gptkbp:research |
government grants
philanthropic donations private investors |
| gptkbp:researchAndDevelopment |
improved survival rates
promising results further studies needed potential for combination therapy reduced tumor size |
| gptkbp:researchAreas |
preclinical
|
| gptkbp:researchFocus |
oncology
|
| gptkbp:route |
intravenous
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea |
| gptkbp:targets |
adults
tumor cells |
| gptkbp:triggerType |
inhibits cell proliferation
|
| gptkbp:usedFor |
treatment of cancer
|